NCT06341127View on ClinicalTrials.gov

Fluoxetine in KCNC1-related Disorder

NACompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

January 17, 2024

Primary Completion Date

November 28, 2024

Study Completion Date

November 28, 2024

Conditions
KCNC1 Related DisorderGenetic DiseaseRare Diseases
Interventions
DRUG

Fluoxetine

Oral fluoxetine daily, 2.5 to 5 mg.

Trial Locations (1)

M5G1R8

Holland Bloorview Kids Rehabilitation Hospital, Toronto

All Listed Sponsors
collaborator

The Hospital for Sick Children

OTHER

lead

Holland Bloorview Kids Rehabilitation Hospital

OTHER

NCT06341127 - Fluoxetine in KCNC1-related Disorder | Biotech Hunter | Biotech Hunter